Is Liraglutide FDA approved?

Liraglutide is FDA approved (FDA status current as of 2010-01-25). This regulatory status is provided for research and educational context only.

Is Oxyntomodulin FDA approved?

Oxyntomodulin is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is Liraglutide administered in research settings?

In research settings, Liraglutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Oxyntomodulin administered in research settings?

In research settings, Oxyntomodulin is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Liraglutide vs Oxyntomodulin

Peptide Comparison

Liraglutide vs Oxyntomodulin

Q: What is the difference between Liraglutide and Oxyntomodulin?

Liraglutide: GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion Oxyntomodulin: Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

Both are Metabolic peptides.

Liraglutide

Victoza

Fat LossFDA ApprovedPrescription

Half-life: 13 hours

52 providers listed

Full Liraglutide profile →

Oxyntomodulin

OXM

Fat LossInvestigationalResearch Only

No providers listed yet

Full Oxyntomodulin profile →

Bottom line

Liraglutide is FDA-approved, while Oxyntomodulin is investigational — the clearest structural difference between them.

Quick Verdict

Liraglutide

Half-life

13 hours

Oxyntomodulin

Half-life

—

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Liraglutide
Further along in FDA review	Liraglutide
More provider options (52 vs 0)	Liraglutide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Liraglutide

Oxyntomodulin

Mechanism Family

Metabolic

Half-life

13 hours

—

FDA Status

approved

investigational

Admin Routes

subcutaneous

subcutaneous, intravenous

Availability

Prescription

Research Only

Providers

52 listed

None listed

FDA Update

Jan 2010

—

Avail. Notes

FDA-approved GLP-1 agonist. Victoza (NDA 022341, Jan 2010) for T2D; Saxenda (NDA 206321, Dec 2014) for weight management. Prescription only. Generic liraglutide available (generic Victoza, Dec 2024; generic Saxenda, Aug 2025).

—

Research Evidence

Liraglutide

Meta-analysis · 8 key studies · most recent 2026

Oxyntomodulin

RCT · 4 key studies · most recent 2026

Research Citations

Liraglutide

Meta-analysis2026 · Diabetes Obes Metab

Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measur…

RCT2022 · JAMA

Semaglutide vs liraglutide for weight loss in adults with overweight or obesity

RCT2015 · New England Journal of Medicine

A randomized, controlled trial of 3.0 mg of liraglutide in weight management

Animal2026 · J Anesth

Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.

+4 more

Oxyntomodulin

RCT2026 · Appetite

Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…

RCT2005 · Diabetes

Oxyntomodulin reduces energy intake and adiposity in overweight and obese subjects

Review2026 · Expert Opin Ther Pat

Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity a…

Review2026 · Endocr Rev

Regulators of Appetite in Mammals - Old and New players.

About Liraglutide

GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion

Research Areas

appetite suppressionweight lossblood sugar regulation

About Oxyntomodulin

Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

Research Areas

appetite suppressionenergy expenditurefat oxidation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Liraglutide

Boxed warning

Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Source: FDA label

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Oxyntomodulin

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Class-based (investigational)

Find Providers

Where to source these peptides

Providers offering

Liraglutide

52 listed

Browse directory →

Providers offering

Oxyntomodulin

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.